首页> 美国卫生研究院文献>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease >Endoplasmic Reticulum Stress Effector CCAAT/Enhancer‐binding Protein Homologous Protein (CHOP) Regulates Chronic Kidney Disease–Induced Vascular Calcification
【2h】

Endoplasmic Reticulum Stress Effector CCAAT/Enhancer‐binding Protein Homologous Protein (CHOP) Regulates Chronic Kidney Disease–Induced Vascular Calcification

机译:内质网应激效应因子CCAAT /增强子结合蛋白同源蛋白(CHOP)调节慢性肾脏病引起的血管钙化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundCardiovascular diseases such as atherosclerosis and vascular calcification are a major cause of death in patients with chronic kidney disease (CKD). Recently, the long‐awaited results of the Study of Heart and Renal Protection trial were reported. This large randomized clinical trial found that an extensive cholesterol‐lowering therapy through the combination of simvastatin and ezetimibe significantly reduced cardiovascular diseases in a wide range of patients with CKD. However, the mechanism by which this cholesterol‐lowering therapy reduces CKD‐dependent vascular diseases remains elusive. The objective of the present study was to determine the contribution of the oxysterol‐induced pro‐apoptotic transcription factor CCAAT/enhancer‐binding protein homologous protein (CHOP) on the pathogenesis of CKD‐dependent cardiovascular diseases through endoplasmic reticulum stress signaling.
机译:背景技术心血管疾病,例如动脉粥样硬化和血管钙化,是慢性肾脏病(CKD)患者死亡的主要原因。最近,报道了期待已久的心脏和肾脏保护研究试验结果。这项大型的随机临床试验发现,通过辛伐他汀和依泽替米贝联合使用的广泛的降低胆固醇的疗法,可显着降低许多CKD患者的心血管疾病。但是,这种降低胆固醇的疗法减少依赖CKD的血管疾病的机制仍然难以捉摸。本研究的目的是通过内质网应激信号确定氧固醇诱导的促凋亡转录因子CCAAT /增强子结合蛋白同源蛋白(CHOP)对依赖CKD的心血管疾病的发病机制的贡献。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号